Inclisiran Added to Statin Plus Ezetimibe: Limited Survival Benefit Evidence

Current Evidence Status

The American College of Cardiology recommends PCSK9 monoclonal antibodies (evolocumab, alirocumab) as the preferred PCSK9 inhibitor class due to demonstrated cardiovascular outcomes benefits in the FOURIER and ODYSSEY Outcomes trials, unlike inclisiran which lacks this evidence 1
The American College of Cardiology states that inclisiran will not have completed cardiovascular outcomes data until 2026-2027, with the ORION-4 and VICTORION-2P trials 1

The American College of Cardiology positions inclisiran as a second-line alternative to PCSK9 mAbs, not as an addition to them, and recommends adding ezetimibe to maximally tolerated statin therapy if LDL-C targets are not met 1
The American College of Cardiology recommends adding a PCSK9 mAb (evolocumab or alirocumab) as the preferred option due to proven cardiovascular outcomes benefits if targets remain unmet after statin plus ezetimibe 1
The American College of Cardiology suggests considering inclisiran in place of a PCSK9 mAb only in specific circumstances, such as demonstrated poor adherence to PCSK9 mAbs, adverse effects from both available PCSK9 mAbs, or inability to self-inject medications 1
The American College of Cardiology recommends considering adding bempedoic acid as third-line therapy if LDL-C remains elevated despite statin, ezetimibe, and PCSK9 inhibitor 1

The American College of Cardiology states that there is no evidence or mechanistic plausibility for combining a PCSK9 mAb with inclisiran, and if inclisiran is used, it must replace (not supplement) the PCSK9 mAb 1

The American College of Cardiology advises against adding inclisiran to patients already on statin plus ezetimibe expecting survival benefits, as the evidence does not exist yet, and recommends prescribing a PCSK9 mAb (evolocumab or alirocumab) first due to proven cardiovascular outcomes benefits 1
The American College of Cardiology suggests reserving inclisiran for patients who cannot tolerate or adhere to PCSK9 mAbs, recognizing the choice of convenience over proven outcomes data 1

The American College of Cardiology recommends first-line non-statin therapy with ezetimibe when maximally tolerated statin therapy fails to achieve target LDL-C levels 2, 3, 4
The American College of Cardiology suggests considering PCSK9 monoclonal antibodies (evolocumab, alirocumab) as second-line non-statin therapy after ezetimibe 2, 5
Inclisiran may be considered only after failure of statin plus ezetimibe therapy, or in patients with documented poor adherence to PCSK9 mAbs, according to the American College of Cardiology 2, 4

The American College of Cardiology recommends adding ezetimibe 10 mg daily to current rosuvastatin 40 mg therapy 2, 3, 5
LDL-C should be reassessed after 4-12 weeks of combination therapy, as suggested by the American College of Cardiology and supported by evidence from Drugs 2, 6
If LDL-C remains ≥70 mg/dL despite statin plus ezetimibe, the American College of Cardiology recommends considering PCSK9 mAb therapy 2, 5

Inclisiran lacks cardiovascular outcomes data unlike PCSK9 mAbs, which is a consideration for its use, as noted by the American College of Cardiology 2, 5
The American College of Cardiology suggests considering inclisiran primarily in patients with demonstrated poor adherence to PCSK9 mAbs, adverse effects from PCSK9 mAbs, or inability to self-inject other medications 2, 4